{"filings":[{"id":1361400,"accession_number":"0001493152-26-031292","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-06-30T20:30:34+00:00","items":["5.02","9.01"],"status":"ready","headline":"Imunon CFO Jeffrey Church to retire; Josh Blacher appointed interim CFO effective July 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Church retires as interim CFO effective July 1, 2026; will continue as consultant at $10,000/month retainer.","Josh Blacher appointed interim CFO via Danforth Health, Inc. at $475/hour; serves as principal financial and accounting officer.","Blacher, 54, has served as CFO for several life sciences companies including BullFrog AI, Inmed, Therapix, and Galmed.","Church's departure is due to retirement and without any disagreements with management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1086516,"accession_number":"0001493152-26-028937","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-06-16T21:30:17+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Imunon shareholders approve 1M share increase to 2018 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing shares available under 2018 Stock Incentive Plan by 1,000,000 to 1,265,004.","Class I directors Frederick J. Fritz and Christine A. Pellizzari were elected with 647,890 and 653,302 votes for, respectively.","WithumSmith+Brown ratified as independent auditor for FY 2026 with 1,715,881 votes for.","Say-on-Pay advisory proposal approved with 580,096 votes for, 115,666 against.","Total shares outstanding: 3,983,342; quorum achieved with 1,808,666 shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843402,"accession_number":"0001493152-26-027201","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-06-04T12:00:40+00:00","items":["1.01","2.03","3.02","5.03","7.01","9.01"],"status":"ready","headline":"IMUNON secures up to $10M through preferred stock and secured notes for Phase 3 trial","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Gross proceeds of $10M from 250 Series A Preferred shares ($2.5M) and secured promissory notes ($7.72M total).","Notes mature in 18 months; A-1 Note at 8% interest, B Note at 5%; secured by assets except IP.","$5M placed in cash collateral; remaining $5M for general corporate purposes including Phase 3 OVATION 3 trial.","Preferred stock is non-convertible, non-voting, 8% annual return; redeemable at 110% of liquidation amount.","Financing structured as non-dilutive with no warrants; management highlights shareholder-friendly terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22763,"accession_number":"0001493152-26-022401","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-05-12T12:05:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.","Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.","With PARP inhibitor maintenance, median OS 65.6 vs 41.4 months (+24.2 months) for IMNN-001 arm.","Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on BLA path.","Strategic reorganization in Feb 2026 reduced operating expenses; R&D expenses up to $2.3M from $2.2M."],"consensus_eps_estimate":-1.1322,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98663,"accession_number":"0001493152-26-021019","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Imunon enters change of control severance agreements with CEO, CMO, and GC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Lindborg gets 2.5x base salary plus target bonus severance; others get 1.5x.","COBRA coverage: 24 months for CEO, 18 months for CMO and GC.","All unvested equity awards fully accelerate upon qualifying termination in change-of-control window.","Effective May 1, 2026; trigger period is 4 months before to 1 year after a change of control.","Benefits require a release of claims; 1-year non-compete covenant applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114274,"accession_number":"0001493152-26-013816","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.","Final Phase 2 OVATION 2 data show median OS improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001+SoC vs SoC alone.","Phase 3 OVATION 3 enrollment ahead of plan; first patient dosed in Q3 2025.","Cash and cash equivalents $8.8M as of Dec 31, 2025; $7M registered direct offering closed Dec 2025.","Strategic reorganization Feb 2026 to reduce expenses and focus on Phase 3 study."],"consensus_eps_estimate":-1.1322,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114273,"accession_number":"0001493152-26-012164","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon registers additional $7M in common stock under existing ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase ATM capacity from $10M to $17M in common stock.","Prior to filing, $4,797,848 of shares had been sold through H.C. Wainwright under the Sales Agreement.","New shares issuable under the existing May 2022 ATM agreement, as amended in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114272,"accession_number":"0001493152-26-005203","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CSO Khursheed Anwer retires effective Feb 20, 2026; transitions to consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Khursheed Anwer will retire as EVP and Chief Scientific Officer on February 20, 2026.","Departure is without disagreement with management; will provide consulting services through Dec 31, 2026.","Consulting retainer of $10,000 per month; 12 months base salary severance and COBRA coverage.","Unvested stock options treated per plan; vested options extended to original expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114271,"accession_number":"0001493152-26-000841","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Imunon interim CFO Graper resigns; Church appointed as interim CFO effective Jan 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberly Graper resigns as interim CFO effective Jan 14, 2026; no disagreements with management.","Jeffrey Church appointed interim CFO, principal financial and accounting officer, effective Jan 14.","Church returns from retirement; he served as EVP/CFO from 2010 to May 2024 and had been consulting.","Under amended agreement, Church receives $30,000 monthly retainer plus $250/hr for hours over 40/month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130647,"accession_number":"0001493152-25-029711","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Imunon raises $7.0M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$7.0M from 1,939,114 shares/pre-funded warrants plus warrants at $3.61/unit.","Warrants exercisable at $3.482/share for 5 years; pre-funded warrants at $0.0001, no expiration.","Offering priced at-the-market under Nasdaq rules; expected to close December 31, 2025.","Net proceeds for general corporate purposes including R&D, capex, and working capital.","Maxim Group LLC is lead placement agent; Brookline Capital Markets is co-placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130646,"accession_number":"0001493152-25-022118","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.","Cash and equivalents $5.3M as of Sept 30, 2025; $4.5M raised from warrant exercises and ATM; runway into Q1 2026.","Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer enrollment exceeding expectations; Phase 2 data showed 13-month OS benefit.","R&D Day on Nov 10 highlighted investigator optimism and translational data; new data presented at SITC and AACR.","PlaCCine DNA vaccine platform proof-of-concept data presented; actively seeking partnerships."],"consensus_eps_estimate":-1.8413,"consensus_eps_actual":-5.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147199,"accession_number":"0001493152-25-012417","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).","Common stock (IMNN) to continue trading on Nasdaq Capital Market without interruption.","CEO notes recent 15% stock dividend and momentum from Phase 2 OVATION 2 trial for IMNN-001 in ovarian cancer.","Phase 3 OVATION 3 trial for IMNN-001 successfully initiated in North America."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147198,"accession_number":"0001493152-25-011597","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q2 net loss narrows to $2.7M, cash $4.7M; first patient dosed in Phase 3 ovarian cancer trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.7M ($2.15/shr) vs $4.8M ($7.64/shr) YoY; operating expenses down 45% to $2.8M.","Cash $4.7M at June 30; received $3.1M in July from warrant exercises and ATM; sufficient into Q4 2025.","First patient dosed July 30 in Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer; 3 sites open, goal 20 by year-end.","Declared 15% stock dividend (0.15 shares/share) payable Aug 21, 2025 to holders of record Aug 7.","Completed 15:1 reverse stock split effective July 25; Nasdaq listing extension granted."],"consensus_eps_estimate":-4.2042,"consensus_eps_actual":-6.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147197,"accession_number":"0001493152-25-011440","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon declares 15% stock dividend, payable Aug 21, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board approved 15% stock dividend: 0.15 shares per common share and equivalents.","Record date August 7, 2025; payment date August 21, 2025; ~448,000 new shares distributed.","CEO cites recent Phase 2 data and Phase 3 advancement as confidence drivers.","Stock dividend rewards shareholders without cash outlay; administered by Equiniti Trust."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147196,"accession_number":"0001641172-25-020652","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Imunon to effect 1-for-15 reverse stock split on July 25, 2025 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split at 1-for-15 ratio effective 12:01 a.m. ET on July 25, 2025.","Outstanding shares to drop from ~31.8M to ~2.1M; fractional shares rounded up.","Split intended to comply with Nasdaq minimum bid price continued listing requirement.","Stock to trade under existing ticker IMNN with new CUSIP 15117N701.","Board set ratio on July 11, 2025; stockholders authorized range of 1-for-5 to 1-for-18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147195,"accession_number":"0001641172-25-020520","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon upsizes ATM equity facility by $4.5M to $10M total capacity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement registering an additional $4.5M of common stock under existing ATM Sales Agreement with H.C. Wainwright.","Total ATM offering capacity increased from $5.5M to $10.0M.","As of July 22, 2025, $1.815M of shares have been sold under the agreement.","Proceeds from prior sales already received; additional funds will support working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147194,"accession_number":"0001641172-25-019541","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Nasdaq panel grants Imunon listing compliance exception; equity plan expanded by 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearing Panel granted Imunon an exception to regain compliance with minimum bid price ($1.00) and stockholders' equity ($5M) requirements.","Company had previously received delisting determination for not meeting minimum bid price and equity requirements.","Imunon must promptly notify Panel of significant events; no assurance of regaining compliance.","Stockholders approved amendment to 2018 Stock Incentive Plan, increasing shares by 2,000,000 to total 3,970,000 shares.","If delisted, stock could suffer material decline and impair capital raising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147193,"accession_number":"0001641172-25-018797","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Imunon shareholders approve increase in authorized shares to 350M and reverse split up to 1:18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 112.5M to 350M; amendment effective July 11, 2025.","Reverse stock split approved at board's discretion with ratio between 1:5 and 1:18; no effective date set.","Approved issuance of shares underlying warrants from May 2025 securities purchase agreement with investors.","Amendment to 2018 Stock Incentive Plan approved; shares available for issuance increased.","Directors elected: Michael H. Tardugno and Dr. Donald P. Braun as Class III directors until 2028 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165812,"accession_number":"0001641172-25-015124","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Imunon terminates interim CFO Gaiero, appoints Kimberly Graper as interim CFO effective June 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated consulting agreement with Monomoy Advisors and David Gaiero as interim CFO, effective June 13, 2025.","Kimberly Graper appointed interim CFO, also serving as principal financial and accounting officer.","Graper has been VP of Finance and Corporate Controller at Imunon since October 2022.","Her annual salary is $244,800 with a target bonus of 30% of base salary.","Graper holds a BS in Accounting from Clemson and a JD from Seton Hall; CPA licensed in New Jersey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165811,"accession_number":"0001641172-25-014279","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Imunon regains Nasdaq minimum bid price compliance; delisting hearing pending on equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price above $1.00 for 10 consecutive days as of June 6, 2025, meeting bid price requirement.","Delisting determination received May 28 for bid price and equity rule violations; hearing requested May 29 stays suspension.","Warrant exercises on May 30 and June 2 provide $2.0M net proceeds, raising equity to $3.0M as of May 31.","Panel hearing will determine continued listing; company expects stock to remain listed until decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165810,"accession_number":"0001641172-25-013051","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Imunon receives Nasdaq delisting notice for bid price and equity non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Delisting determination letter received May 28, 2025 for failure to regain $1.00 minimum bid price by May 27, 2025.","Company not eligible for additional extension due to not meeting $5M minimum stockholders' equity requirement.","Separate deficiency notice on May 19, 2025 for non-compliance with minimum stockholders' equity under Rule 5550(b)(1).","Company will request a hearing by June 4, 2025 to appeal; trading suspension stayed pending hearing decision.","Plans to propose a reverse stock split to regain compliance, subject to board and stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165809,"accession_number":"0001641172-25-012395","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Imunon raises $3.25M upfront in private placement; warrants could add $6.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement raises $3.25M upfront from common stock and pre-funded warrants.","Warrants to purchase up to 14,444,446 shares at $0.45 per share, subject to stockholder approval, expire three years later.","If fully exercised on a cash basis, warrants would yield additional $6.5M in gross proceeds.","Proceeds intended for working capital and general corporate purposes.","Offering priced at-the-market under Nasdaq rules; expected to close May 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165808,"accession_number":"0001641172-25-011999","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Imunon withdraws S-1 registration statement for proposed public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company requested SEC consent to withdraw S-1 (File No. 333-286403) on May 22, 2025.","Imunon determined not to pursue the public offering and withdrew the registration statement.","Registration statement had been amended on May 13 and May 19, 2025 before withdrawal.","Withdrawal deemed granted May 22, 2025 unless SEC objects within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165807,"accession_number":"0001641172-25-011601","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Imunon receives Nasdaq notice for failing to meet $2.5M stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Imunon on May 19, 2025 of non-compliance with minimum stockholders' equity of $2.5M (Listing Rule 5550(b)(1)).","Company has until July 3, 2025 to submit a compliance plan; if accepted, Nasdaq may grant up to 180 days to regain compliance.","Failure to regain compliance could lead to delisting; company would have right to a hearing before Nasdaq Hearings Panel.","Deficiency is unrelated to prior notice regarding minimum bid price requirement disclosed in November 2024.","Company evaluating options to regain compliance but cautions no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165806,"accession_number":"0001641172-25-009775","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Imunon exchanges warrants for 2.921M shares, representing 19.98% of outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,921,000 shares to warrant holders in exchange for warrants exercisable for 5,000,000 shares.","Exchange closes May 13, 2025; shares issued under Section 3(a)(9) exemption, no restrictive legends.","Warrant holders waived certain anti-dilution provisions for 45 days and agreed to lock-up until May 14.","Exchange reduces potential dilution by 2,079,000 shares compared to full warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165805,"accession_number":"0001641172-25-009570","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.","Cash and equivalents $2.9M as of 2025-03-31; company expects funding into late Q2 2025 only.","First trial site initiated for Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.","Abstract for OVATION 2 updated survival analysis accepted for oral presentation at 2025 ASCO Annual Meeting.","Appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer effective 2025-02-18."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183371,"accession_number":"0001641172-25-000207","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IMUNON finalizes Phase 3 OVATION 3 trial design with FDA for IMNN-001 in advanced ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligns on Phase 3 protocol for IMNN-001 plus NACT vs NACT alone in newly diagnosed advanced ovarian cancer (stage 3/4).","Primary endpoint is overall survival; secondary endpoints include surgical response, clinical response, time to second-line treatment.","Phase 2 data showed median OS of 46 months for IMNN-001+NACT vs 33 months for SoC, a 13-month improvement.","Company initiating trial sites; IMNN-001 manufactured at in-house facility in Huntsville, AL.","Conference call on March 25, 2025 at 2:00 p.m. ET to discuss Phase 3 OVATION 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183370,"accession_number":"0001493152-25-008457","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon reports FY2024 net loss $18.6M, OS benefit 13mo for IMNN-001, Phase 3 start Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.6M ($1.62/share) in 2024 vs $19.5M in 2023; cash $5.9M at year-end, sufficient into late Q2 2025.","OVATION 2: median OS 13 months (HR 0.69) with IMNN-001 + chemo vs SOC alone; >1/3 survived >36 months.","Phase 3 pivotal trial of IMNN-001 to begin Q1 2025 after positive End-of-Phase 2 and CMC meetings with FDA.","New CMO Douglas V. Faller, M.D., Ph.D. appointed Feb 18, 2025; leads clinical strategy for IMNN-001.","PlaCCine vaccine Phase 1: IMNN-101 safe, induced 2-4x NAb titers; seeks partners for further development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183369,"accession_number":"0001493152-25-005536","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.","Lead program IMNN-001 for advanced ovarian cancer on track to enter Phase 3 pivotal trial in Q1 2025.","Compensation: $480k salary, 40% bonus target, inducement options for 100,000 shares with 4-year vesting.","Dr. Faller brings 30+ years of oncology/immunology experience from Takeda, Skyhawk, and academic roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199959,"accession_number":"0001493152-24-048008","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Imunon receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bid price closed below $1.00 for 30 consecutive business days as of Nov 26, 2024.","Compliance period runs until May 27, 2025; must close at $1.00+ for 10 consecutive days.","If not cured by May 27, 2025, may qualify for additional 180-day period under certain conditions.","Company may consider options to regain compliance; no immediate effect on listing.","Ticker IMNN continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199958,"accession_number":"0001493152-24-043933","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.","Cash, investments of $10.3M; expects to fund operations into Q3 2025.","OVATION 2 topline: 11.1-month OS improvement, hazard ratio 0.74 in ITT; 15.7-month OS in per-protocol.","Plan 500-patient Phase 3 study start Q1 2025; End-of-Phase 2 FDA meeting later in November 2024.","Raised $10M gross proceeds in July 2024 registered direct offering; added General Counsel and SVP of Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199957,"accession_number":"0001493152-24-039646","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Imunon appoints Susan Eylward as General Counsel and Corporate Secretary; grants inducement stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Eylward appointed General Counsel and Corporate Secretary effective October 7, 2024.","Initial salary of $340,000; eligible for 30% annual performance bonus.","Received inducement option for 50,000 shares vesting over four years; exercise price = Oct 7 closing price.","Another Q4 2024 hire received inducement option for 60,000 shares under same terms.","Options granted under Nasdaq Listing Rule 5635(c)(4) as material inducement to employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215968,"accession_number":"0001493152-24-034716","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon resumes at-the-market stock offering after previous suspension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sept 3, 2024, Imunon filed a new prospectus supplement to resume sales under the existing ATM agreement.","The ATM program had been suspended on July 30, 2024 via termination of the sales prospectus.","The ATM Agreement (May 2022, amended May 2024) with H.C. Wainwright remains in force.","Legal opinion on share validity from Covington & Burling filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215967,"accession_number":"0001493152-24-031882","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.","Positive OVATION 2 topline: 11.1-month median OS improvement (HR=0.74) in ITT; 15.7-month gain in per-protocol (HR=0.64).","Phase 3 study of IMNN-001 planned to start Q1 2025 after End-of-Phase 2 FDA meeting.","Raised $10M gross ($9M net) in July 2024 registered direct offering; cash + investments $5.3M at June 30, funding into Q3 2025.","IMNN-101 Phase 1 COVID booster trial enrolling; topline data expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215966,"accession_number":"0001493152-24-029871","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon files prospectus supplement for 5M share registered direct offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 5,000,000 shares of common stock (par value $0.01).","Prospectus supplement filed under Registration Statement No. 333-279425 on August 1, 2024.","Use of proceeds not specified; legal opinion on share validity included as exhibit.","Offering is a direct sale without underwriter disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215965,"accession_number":"0001493152-24-029697","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"IMUNON announces $10M registered direct offering of 5M shares and warrants at $2.00, closing Aug 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling 5,000,000 common shares and warrants to purchase 5,000,000 shares at $2.00 per unit.","Warrants exercisable immediately at $2.00/share for 5.5 years from issuance.","Gross proceeds of $10 million; net proceeds for working capital and general corporate purposes.","Company terminated the ATM prospectus; ATM agreement remains in effect but no sales until new filing.","Closing expected on or about August 1, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215964,"accession_number":"0001493152-24-029517","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).","In patients receiving ≥3 doses, OS extended by 15.7 months (45.1 vs 29.4); HR 0.64.","PARP inhibitor subgroup: median OS not reached in IMNN-001 arm vs 37.1 months; HR 0.41.","PFS primary endpoint: 3-month improvement (14.9 vs 11.9); HR 0.79.","Company plans registrational Phase 3 study to begin in Q1 2025; End-of-Phase 2 meeting with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235446,"accession_number":"0001493152-24-023638","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Imunon 2024 annual meeting: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Stacy R. Lindborg and James E. Dentzer elected as directors with 1.63M and 1.56M votes for.","Ratification of WithumSmith+Brown as auditor for FY2024 approved: 3.56M for, 52,812 against.","Say-on-pay advisory vote approved: 1.11M for, 187,627 against, 400,735 abstentions.","Frederick Fritz, Christine Pellizzari, Donald Braun, Michael Tardugno continue as directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235445,"accession_number":"0001493152-24-020543","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Jeffrey Church retiring June 1; David Gaiero appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Church to retire as CFO effective June 1, 2024; will serve as consultant through Dec 31, 2024.","Church receives retirement bonus of $428,615; monthly consulting retainer of $10,000 plus $250/hr over 40 hrs.","David Gaiero appointed CFO via Monomoy Advisors; monthly fee of $35,000 starting June 1, 2024.","Gaiero is a partner at Monomoy, served as CFO of Cyteir Therapeutics and interim CFO at Wave Life Sciences.","Church's vested stock options extended to original expiration; unvested options treated per plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235444,"accession_number":"0001493152-24-018791","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.","Cash and investments $9.8M; believes funding sufficient through end of 2024.","Stacy Lindborg appointed President and CEO effective May 13, 2024; previously a director and Co-CEO of BrainStorm.","OVATION 2 Study of IMNN-001 in advanced ovarian cancer: interim PFS delay ~3 months, OS improvement ~9 months; final readout mid-2024.","FDA cleared IND for IMNN-101 seasonal COVID booster; Phase 1 starting Q2 2024. Received $1.3M non-dilutive from NJ NOL sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235443,"accession_number":"0001493152-24-018166","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Imunon appoints Dr. Stacy R. Lindborg as President and CEO effective May 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement: $567,000 base salary, 100% target bonus, 225,000 stock options vesting over 4 years, $200,000 sign-on bonus.","Dr. Lindborg brings 30 years of pharma/biotech experience; most recently co-CEO of BrainStorm Cell Therapeutics (BCLI).","Phase 2 OVATION 2 topline results for IMNN-001 (ovarian cancer) expected by mid-summer; Phase 1 COVID-19 vaccine data by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235442,"accession_number":"0001493152-24-014284","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Imunon regains Nasdaq minimum bid price compliance, deficiency resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Imunon on April 10, 2024, that compliance with Listing Rule 5550(a)(2) was regained after 10 consecutive trading days with bid price over $1.00.","The deficiency notice from December 26, 2023, is now fully resolved; stock maintains listing on Nasdaq Capital Market under symbol IMNN.","Executive Chairman notes topline results from OVATION 2 Study for IMNN-001 in advanced ovarian cancer expected mid-2024.","Company plans to begin Phase 1 study of COVID-19 booster vaccine (IMNN-101) in Q2 2024 after FDA IND clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253255,"accession_number":"0001493152-24-011614","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon reports 2023 net loss $19.5M; OVATION 2 shows ~30% PFS delay, ~9 months OS improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.5M ($2.16 per share) vs $35.9M ($5.03 per share) in 2022; operating expenses down 17%.","Cash, investments and accrued interest $15.7M at year end; expects funding into Q4 2024.","Interim OVATION 2 data: ~30% delay in disease progression or death; ~9 month OS improvement in treatment arm vs control.","Phase 1/2 trial of IMNN-001 + bevacizumab enrolling at MD Anderson and MSK.","PlaCCine COVID-19 booster IND submitted; Phase 1 proof-of-concept expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253254,"accession_number":"0001493152-24-010195","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Imunon amends bylaws to revise voting thresholds and adjournment procedures per DGCL changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendments effective March 15, 2024; Amended and Restated Bylaws filed as Exhibit 3.1.","Amendments revise voting thresholds required for stockholder approval of certain matters.","Adjournment procedures for stockholder meetings modified to reflect recent changes to Delaware General Corporation Law.","Periodic bylaw review triggered by recent DGCL amendments; changes became immediately effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253253,"accession_number":"0001493152-24-009684","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Imunon CEO Corinne Le Goff resigns; Executive Chairman Tardugno assumes interim leadership","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Corinne Le Goff resigned as President, CEO, and Board member, effective March 15, 2024, to pursue another opportunity.","Resignation was not due to any disagreement with the Company regarding operations, policies, or practices.","Executive Chairman Michael H. Tardugno (former CEO) will lead day-to-day operations until a successor is named.","Active CEO search is underway; development strategy and key program milestones remain unchanged.","Milestones: Phase 1 trial of IMNN-101 (COVID-19 booster) prep ongoing; OVATION 2 topline data for IMNN-001 expected summer 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270728,"accession_number":"0001493152-23-046587","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Imunon receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Dec. 26, 2023; bid price closed below $1.00 for 30 consecutive business days.","Given 180-day cure period until June 24, 2024; must have bid price >=$1.00 for 10 consecutive business days.","If not compliant by June 24, 2024, may be eligible for second 180-day compliance period subject to other listing standards.","Failure to cure could result in delisting; company may appeal any delisting determination.","No immediate effect on listing; shares continue trading on Nasdaq Capital Market under IMNN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270727,"accession_number":"0001493152-23-044323","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.","Base salary of $475,000, target bonus of 50%; received inducement option for 80,000 shares at $0.88/share and 20,000 restricted shares.","He will oversee clinical programs including IMNN-001 (IL-2) for ovarian cancer; topline data from OVATION 2 Study expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270726,"accession_number":"0001493152-23-040802","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.","Cash and equivalents $19.5M as of Sept 30, 2023; expects $1.8M from NJ NOL sales.","Interim OVATION 2 data: PFS improved ~33% in treatment arm; OS improved ~9 months; median PFS 23.7 months with PARP inhibitor combo vs 15.7 months control.","Enrolled first patient in Phase 1/2 trial of IMNN-001 + bevacizumab at MD Anderson; IND filing for IMNN-101 COVID booster on track for Q1 2024.","Entered CRADA with NIAID for Lassa virus vaccine evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287634,"accession_number":"0001493152-23-027452","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Imunon Q2 net loss narrows to $5.6M; cash $24.1M; on track for COVID IND Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2023 $5.6M ($0.61/sh) vs $6.0M ($0.87/sh) in Q2 2022; operating expenses down 10% YoY.","Cash and investments $24.1M at June 30, 2023; plus planned $1.8M from NOL sales; expected to fund operations through 2024.","On track to submit IND for seasonal COVID-19 vaccine (IMNN-101) in Q1 2024; FDA confirmed platform acceptability.","Unveiled new cGMP manufacturing facility at HudsonAlpha to support R&D and lower costs.","Preclinical data show PlaCCine vaccines elicit durable T-cell responses > 14 months, higher than mRNA vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307881,"accession_number":"0001493152-23-021447","cik":749647,"company_name":"Imunon, Inc.","ticker":"IMNN","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"IMUNON stockholders approve 2018 Stock Incentive Plan amendment, increasing authorized shares to 1,970,000","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2018 Stock Incentive Plan, increasing shares available from 940,000 to 1,970,000.","Re-elected directors Frederick J. Fritz and Christine A. Pellizzari to serve until 2026 Annual Meeting.","Ratified WithumSmith+Brown as independent auditor for fiscal year 2023.","Advisory Say-on-Pay vote approved; future Say-on-Pay votes set for every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9685882.591304349,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-15T23:59:59+00:00|307881"}